Gout: History and Discovery
Gout is one of the oldest diseases recorded by humankind, and it has no single inventor or discoverer. The painful joint attacks we now call gout were described in ancient Mesopotamia and Egypt, named and clinically characterised by the physicians of ancient Greece, and written about continuously for more than 2,000 years. What does have a traceable discovery history is gout's underlying cause. That story runs from the first sight of urate crystals under an early microscope in 1679, to the demonstration that gout patients carry excess uric acid in their blood in 1848, to the final proof in 1961 that monosodium urate crystals are what actually inflame the joint. This page separates the ancient clinical recognition of the disease from the much later scientific discovery of why it happens, and it names verified people, dates, and "firsts" only where the historical record supports them.
Table of Contents
- An Ancient Disease
- Hippocrates and "Podagra"
- Why It Is Called "Gout" — Gutta and the Humours
- The Disease of Kings
- Sydenham's Classic Treatise (1683)
- Leeuwenhoek Sees the Crystals (1679)
- Garrod and Uric Acid (1848) — the Modern Cause
- Confirming Crystals Cause Inflammation (1961)
- Modern Understanding
- Research Papers and References
- Connections
An Ancient Disease
Gout has accompanied human beings for as long as we have kept medical records, and it is frequently described as one of the oldest diseases known to medicine. There was no moment of "discovery" of the illness itself, and no individual can be credited with finding it: the abrupt, agonising swelling of a single joint — most often the base of the big toe — is so distinctive and so dramatic that it was recognised independently by ancient cultures across the world. The earliest references commonly cited reach back to the third millennium BCE. The scholarly history of gout by Nuki and Simkin notes that a condition answering to gout was recorded by the Egyptians around 2640 BCE, and ancient Mesopotamian and later Chinese, Indian, and Roman medical traditions all describe the same unmistakable affliction of the foot and toe.
It is worth pausing on why this matters for honesty. Many "history of medicine" stories feature a single brilliant founder, but gout is not one of them. The disease was known to antiquity; what changed across the centuries was not the discovery of gout but the slow, hard-won discovery of what causes it. For most of human history the swollen joint was attributed to lifestyle, fate, or an imbalance of bodily fluids, and effective relief — when it existed at all — was stumbled upon empirically rather than reasoned from any understanding of the underlying chemistry.
One of those empirical treatments is itself ancient and well documented. Extracts of the autumn crocus (Colchicum autumnale), the natural source of the drug colchicine still used for gout today, were employed against joint pain in antiquity; the specific use of colchicum for gout is often attributed in the historical literature to the sixth-century Byzantine physician Alexander of Tralles. Remarkably, a remedy whose mechanism would not be understood for well over a thousand years was already recognised as helping the gouty joint — a vivid illustration of how far the practical management of gout ran ahead of any theory of its cause.
Hippocrates and "Podagra"
The first systematic, recognisably clinical account of gout in the Western tradition belongs to the Hippocratic Corpus, the body of medical writings associated with the Greek physician Hippocrates of Kos in the fifth century BCE (around 400 BCE). These writings did not invent the disease — it was already old — but they named and characterised it with a precision that still impresses modern rheumatologists. The Greek term used was podagra, literally a "seizure" or "trap" of the foot (from pous, foot, and agra, a catching or seizing), reflecting the way an attack so often grips the great toe. Hippocratic writing also referred to it, memorably, as a disease that left its sufferer unable to walk.
Several Hippocratic aphorisms about gout are famous precisely because they have held up over two and a half millennia. Three in particular are repeatedly cited in the historical literature: that eunuchs do not develop gout; that a woman does not develop gout before the menopause; and that a man does not develop gout before puberty. We now understand the kernel of truth behind these observations — sex hormones strongly influence uric-acid handling, and oestrogen is uricosuric, so premenopausal women clear urate more readily — but the ancient authors had no concept of uric acid at all. They were recording a real epidemiological pattern by sharp clinical observation alone.
It should be said plainly that these aphorisms describe primary gout and are generalisations, not laws: with modern diets, medications, and kidney disease, gout certainly does occur in younger people and in premenopausal women. What the Hippocratic observations represent historically is the moment when gout passed from a merely noticed affliction into a described, named, and pattern-recognised clinical entity — the foundation on which every later investigator built.
Why It Is Called "Gout" — Gutta and the Humours
The modern English word gout is much younger than the disease, and its origin is itself a small history lesson in how people once thought about illness. The word entered English around the end of the thirteenth century, by way of the Old French goutte, from the Latin gutta, meaning "a drop." The name had nothing to do with the symptoms directly; it encoded a theory of the cause that prevailed in the medieval world.
That theory was humoralism. Classical and medieval medicine held that health depended on the balance of four bodily "humours" (blood, phlegm, yellow bile, and black bile). Disease arose when a humour became corrupted or excessive, and certain illnesses were explained as a noxious humour dropping, drop by drop, out of the bloodstream and settling into a vulnerable part of the body. Gout was understood as exactly this: a morbid humour falling like drops into the joint, where it caused the heat, swelling, and exquisite pain. The Latin gutta — the drop — named the supposed mechanism, and the word stuck even after the humoral theory it embodied was abandoned. (The historical record even preserves an early user of the term in this sense in thirteenth-century England, the Dominican Randolphus of Bocking, though the word's broader adoption is what matters here.)
This etymology is a useful reminder that disease names often fossilise obsolete ideas. The "drop" in gout is not urate and not crystal — concepts that lay centuries in the future — but a humour, imagined as a liquid trickling into the joint. The eventual replacement of that picture with the real chemistry of uric acid and urate crystals is the central thread of everything that follows on this page.
The Disease of Kings
Across the medieval and early-modern centuries, gout acquired a second identity that is as much social as medical: it became known as "the disease of kings" and the "king of diseases." The association was not arbitrary. Gout attacks are strongly provoked by a rich diet heavy in meat and seafood and by liberal alcohol — in particular the fortified wines and ports favoured by the wealthy — and for most of history only the affluent could afford to eat and drink that way habitually. A disease that clustered among the prosperous, the powerful, and the indulgent inevitably gathered an aura of luxury, even of a perverse status symbol.
The roster of historical sufferers became part of the legend — kings, statesmen, and men of letters across the centuries are recorded as gouty — and the condition was often depicted in art and satire as the price of high living, the swollen foot propped on a stool while its owner clutched a wine glass. The flip side of "disease of kings" was the companion observation, already present in Hippocratic writing, that gout was rare among the poor, whose diets were leaner and whose drink was meaner. The wealthy got the gout; the labourer, eating less meat and drinking less wine, largely did not.
This social history is more than colour. The dietary and alcohol associations that earned gout its royal nickname were genuine clinical observations, and they pointed, however indirectly, at something true about the cause: that what a person eats and drinks loads the body with the raw material of the disease. Centuries before anyone could name uric acid, the link between purine-rich feasting, heavy drinking, and the gouty toe was being recorded in the very nickname of the illness. The science, when it finally arrived, would explain the king's affliction rather than overturn it.
Sydenham's Classic Treatise (1683)
If one pre-modern description of gout deserves to be singled out, it is that of the English physician Thomas Sydenham (1624–1689), often called "the English Hippocrates." In 1683 Sydenham published his treatise on gout (the Latin Tractatus de Podagra et Hydrope — a treatise on gout and dropsy), and his account of a gout attack is still quoted today as perhaps the most vivid and exact clinical picture of the disease ever written. He described the sufferer going to bed in apparent health and being woken in the small hours by a pain in the great toe so severe that the weight of a bedsheet, or the vibration of someone walking across the room, was unbearable.
What gives Sydenham's treatise its peculiar authority is that he was himself a lifelong, severe sufferer of gout, and he wrote from the inside. His description captures not just the timing and the savagery of the night-time attack but the recurring, episodic nature of the disease, its predilection for men, and the way attacks tend to recur and to spread over years — observations that map directly onto the modern clinical course of gout. He drew the long-recognised distinction between gout and rheumatism more clearly, and his work became the standard reference for generations of physicians.
Sydenham, crucially, still worked within the framework of his time: he had no notion of uric acid, and his treatments and explanations belonged to the pre-chemical era. His genius was observational, not mechanistic. But by sharpening the clinical portrait of gout to near-perfection, he set the stage for the question that the next two centuries would finally answer — not "what does gout look like?", which he had settled, but "what, chemically, is it?"
Leeuwenhoek Sees the Crystals (1679)
The first physical clue to the real nature of gout came not from a physician at all, but from the Dutch draper and pioneering microscopist Antonie van Leeuwenhoek. In 1679, using one of the single-lens microscopes he had built and ground himself, Leeuwenhoek examined the chalky white material taken from a gouty tophus — the firm, pale deposit that forms in and around joints in long-standing gout — and became the first human being to see what it was actually made of.
His own words, preserved in the historical record, capture the moment of surprise: he had expected the chalky substance to be formless, but instead he found that it "consisted of nothing but long, transparent little particles, many pointed at both ends." He had, in fact, observed the needle-like crystals of monosodium urate that are the physical hallmark of gout — the very crystals that modern laboratories still look for to confirm the diagnosis. It is a genuine "first" and an important one, and it is correctly described here with its limit.
That limit is essential to state honestly: Leeuwenhoek saw the crystals but did not know what they were. He had no way to determine their chemical nature, did not connect them to any substance in the blood, and did not propose a cause of gout. His achievement was observational — the first sighting of the gouty crystal — and it would take more than a century before the chemistry caught up. The chalk of the tophus was later shown to contain uric acid (by William Hyde Wollaston in 1797, working on a tophus from his own ear), but the full significance of Leeuwenhoek's pointed little particles would only become clear with the work of Garrod in the following century, and would not be definitively tied to the joint inflammation until 1961.
Garrod and Uric Acid (1848) — the Modern Cause
The decisive step from describing gout to explaining it belongs to the English physician Sir Alfred Baring Garrod (1819–1907), widely regarded as a founder of modern rheumatology. In 1848 Garrod demonstrated that patients with gout carry an excess of uric acid in their blood — and, just as importantly, that this excess was specific to gout: it was not found in patients with acute rheumatism or with the kidney disease then known as Bright's disease. For the first time, gout had a measurable chemical signature, and the centuries-old "drop of humour" gave way to a real, quantifiable abnormality of body chemistry.
Garrod is also remembered for an elegant, simple bedside method now known as the "thread test." A thread was suspended in a small quantity of the patient's blood serum (or urine) that had been gently acidified and left to stand; in gouty samples, uric acid would come out of solution and deposit as crystals along the thread, which could then be seen and even weighed. It was a remarkably practical, almost homespun way to detect and roughly quantify hyperuricaemia, and it is often cited as one of the very first clinical chemistry tests. A point of accuracy: while Garrod's demonstration of excess blood uric acid dates to 1848, the published description of the thread method itself came somewhat later, around 1859 — the two achievements are sometimes conflated, but the historical sources place the formal thread test in the late 1850s. Either way, the conceptual breakthrough — gout as a disorder of uric-acid excess — is rightly dated to 1848.
Garrod went further and proposed, correctly in essence, that the disease arose either from overproduction of uric acid or from the kidney's failure to excrete it adequately — the very dichotomy ("over-producers" versus "under-excretors") still taught today. With Garrod, gout became a metabolic disease of uric acid rather than a mysterious humoral affliction. The cause that antiquity had attributed to fate and the Middle Ages to a dropping humour now had a name: uric acid. What remained was to prove exactly how that excess uric acid actually injured the joint.
Confirming Crystals Cause Inflammation (1961)
Garrod had established that gout was a disease of excess uric acid, and Leeuwenhoek had long before glimpsed crystals in a tophus, but a crucial link remained unproven for another century: did the urate crystals actually cause the acute attack, or were they merely a by-product of a joint already inflamed for some other reason? The definitive answer came in 1961, from the American rheumatologists Daniel J. McCarty and Joseph L. Hollander, in a now-classic paper titled "Identification of Urate Crystals in Gouty Synovial Fluid," published in the Annals of Internal Medicine.
Working at the University of Pennsylvania, Hollander first noticed crystals in ordinary microscopy of joint fluid, and McCarty then used a compensated polarised-light microscope to identify them rigorously. They demonstrated that needle-shaped monosodium urate (MSU) crystals were consistently present in the synovial fluid drawn from acutely inflamed gouty joints. This was the proof that closed the loop: the crystals were not incidental but were found right at the scene of the acute attack, and subsequent work showed that injecting such crystals could provoke an inflammatory response — establishing MSU crystals as the direct trigger of gouty inflammation.
The 1961 work did more than settle a long-standing question; it transformed clinical practice. Examining joint fluid under polarised light for the characteristic negatively birefringent, needle-shaped urate crystals became, and remains, the gold-standard test for diagnosing gout with certainty — a direct descendant of Leeuwenhoek's first astonished glimpse in 1679, now placed on a firm scientific footing. With McCarty and Hollander, the chain from clinical recognition (Hippocrates) through chemical cause (Garrod) to inflammatory mechanism (crystals) was complete.
Modern Understanding
Modern medicine understands gout as a disorder of uric-acid metabolism in which a persistently raised blood urate level (hyperuricaemia) leads, in susceptible people, to the deposition of monosodium urate crystals in and around joints. When those crystals are shed into the joint space, they are engulfed by immune cells and ignite an intense, self-amplifying inflammatory cascade — we now know this involves activation of the NLRP3 inflammasome and a surge of the inflammatory signal interleukin-1 beta — producing the sudden, ferocious pain that Sydenham described so vividly more than three centuries ago. Uric acid itself is the end-product of the breakdown of purines, which come both from the body's own cells and from purine-rich foods such as red meat, organ meats, certain seafood, and from alcohol, especially beer.
That mechanistic picture vindicates, rather than discards, the older history. The ancient link to rich food and heavy drinking (the "disease of kings") is precisely the dietary purine and alcohol load that raises urate. The Hippocratic observations about hormones (eunuchs, premenopausal women) reflect the real effect of sex hormones on urate excretion. The "drop" of the medieval name turns out to be, in a sense, prophetic of crystals depositing into the joint — though the deposit is urate, not humour. Each ancient and early-modern observation captured a genuine fragment of a truth that only the chemistry of uric acid could fully explain.
Treatment, too, now spans the whole arc of this history. The ancient autumn-crocus remedy survives as colchicine, still used to calm acute attacks. Garrod's insight that gout is a disease of uric-acid excess underpins the urate-lowering drugs — above all the xanthine-oxidase inhibitor allopurinol, introduced in the 1960s — that prevent attacks by reducing the body's urate burden, and modern biologic agents that block interleukin-1 target the very inflammatory pathway the crystals switch on. Gout, an affliction as old as civilisation and once attributed to fate, luxury, or a falling humour, is today one of the most thoroughly understood and most treatable forms of arthritis. Its history is a model of how careful observation across millennia, joined at last to laboratory science, turns an ancient mystery into a manageable disease.
Research Papers and References
The references below combine the key peer-reviewed historical reviews of gout and the landmark primary papers in its discovery with curated PubMed topic-search links. Ancient and early-modern primary texts — the Hippocratic Corpus, Sydenham's Tractatus de Podagra et Hydrope (1683), and Leeuwenhoek's microscopical letters — are named in the article as historical sources rather than as modern citations. Each external link opens in a new tab; where a stable DOI or PMID was confidently verified it is given directly, otherwise a PubMed topic search is provided.
- Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Research & Therapy. 2006;8(Suppl 1):S1. — doi:10.1186/ar1906 (PMID: 16820040)
- McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Annals of Internal Medicine. 1961;54:452-460. — doi:10.7326/0003-4819-54-3-452 (PMID: 13773775)
- Schwartz S. Disease of distinction: the history of gout (Hippocratic aphorisms and the social history of the disease) — PubMed: history of gout and podagra
- Storey GD. Alfred Baring Garrod (1819-1907). Rheumatology (Oxford). — PubMed: Alfred Baring Garrod and uric acid
- Garrod's demonstration of excess uric acid in gout (1848) and the thread test — PubMed: Garrod thread test and uric acid
- Antonie van Leeuwenhoek and the first observation of urate crystals from a tophus (1679) — PubMed: Leeuwenhoek and gouty tophus crystals
- Monosodium urate crystals, the NLRP3 inflammasome, and acute gouty inflammation — PubMed: urate crystals and the NLRP3 inflammasome
- Thomas Sydenham and his 1683 treatise on gout (clinical description) — PubMed: Sydenham's treatise on gout
- Colchicine, autumn crocus (Colchicum autumnale), and the ancient treatment of gout — PubMed: colchicine and the history of gout treatment
- Hyperuricaemia, urate handling, and the pathophysiology of gout (modern review) — PubMed: hyperuricaemia and gout pathophysiology
- Sex hormones, oestrogen, and the lower urate levels of premenopausal women — PubMed: oestrogen and uric-acid excretion
- Allopurinol and xanthine-oxidase inhibition in the modern treatment of gout — PubMed: allopurinol and urate-lowering therapy
- Diet, alcohol, purines, and serum urate — the dietary basis of the "disease of kings" — PubMed: diet, alcohol, and gout risk